 DURHAM, N.C., Aug. 30, 2021 GLOBE NEWSWIRE -- Bioventus Inc. Nasdaq: BVS Bioventus or the Company, a global leader in innovations for active healing, has elected to make a 50 million escrow payment pursuant to its Option and Equity Purchase Agreement with CartiHeal Ltd., signaling its intent to move forward with an acquisition of CartiHeal. The Companys decision came following its review of a statistical analysis report of the pivotal clinical trial of the AgiliTM-C implant, reimbursement coding analysis and significant market diligence including surgeon interviews with respect to Agili-Cs commercialization opportunity and ultimate market potential. 